Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meloxicam Doses vs Placebo in Rheumatoid Arthritis
NCT00042068Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2002
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of meloxicam in rheumatoid arthritis (RA) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: American College of Rheumatology 20% Response at 12 weeks. Started Jun 2002; status: completed.
02
Drugs
meloxicam
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00042068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00042068.